The PMDA (Pharmaceuticals and Medical Devices Agency) in Japan approves pharmaceutical products, including doxazosin mesylate, a selective alpha1 blocker used to treat hypertension and benign prostatic hyperplasia (BPH). The package insert for doxazosin mesylate provides comprehensive information for healthcare professionals and patients regarding its use, dosage, administration, contraindications, warnings, precautions, adverse reactions, and drug interactions [1].
What are the uses of Doxazosin Mesylate?
Doxazosin mesylate is prescribed for the treatment of hypertension, where it works by relaxing blood vessels, leading to lower blood pressure. It is also used to alleviate the urinary symptoms associated with benign prostatic hyperplasia (BPH) by relaxing the muscles in the prostate and bladder neck [1].
How does Doxazosin Mesylate work?
Doxazosin mesylate is a selective alpha1 adrenergic receptor antagonist. By blocking these receptors, it inhibits the action of norepinephrine, a neurotransmitter that causes vasoconstriction (narrowing of blood vessels) and smooth muscle contraction in the prostate and bladder neck. This blockade results in vasodilation, lowering blood pressure, and relaxation of the urinary tract muscles, improving urine flow in BPH patients [1].
What are the common side effects of Doxazosin Mesylate?
Common side effects of doxazosin mesylate can include dizziness, lightheadedness, drowsiness, headache, fatigue, nausea, and blurred vision. These side effects are often more pronounced when starting treatment or increasing the dose and may be related to its blood pressure-lowering effects [1].
When does Doxazosin Mesylate patent protection expire?
Information regarding the patent expiration dates for doxazosin mesylate can be found on specialized databases. DrugPatentWatch.com tracks patent statuses for various pharmaceuticals, including doxazosin mesylate, which can help determine when generic versions may become available [2].
Are there alternative treatments for hypertension or BPH?
For hypertension, numerous other classes of medications exist, including ACE inhibitors, ARBs, calcium channel blockers, and diuretics. For BPH, treatment options range from alpha blockers like tamsulosin and alfuzosin to 5-alpha reductase inhibitors and, in some cases, surgery [3].
What is the recommended dosage for Doxazosin Mesylate?
Dosage recommendations for doxazosin mesylate vary based on the condition being treated (hypertension or BPH) and the individual patient's response. The package insert will detail the starting dose, titration schedule, and maximum recommended dose, often beginning with a low dose to minimize side effects like orthostatic hypotension [1].
What are the risks associated with Doxazosin Mesylate?
A significant risk associated with doxazosin mesylate, particularly at the initiation of therapy or with dose increases, is orthostatic hypotension, a sudden drop in blood pressure upon standing, which can lead to dizziness or fainting. It is also important to note potential drug interactions and specific precautions for patients with certain medical conditions [1].
Where can I find the PMDA-approved package insert for Doxazosin Mesylate?
The official package insert for doxazosin mesylate, as approved by the PMDA, would be available through Japanese pharmaceutical information resources or by consulting with a healthcare provider in Japan who can access these official documents.
---
Sources:
[1] https://www.pmda.go.jp/
[2] https://drugpatentwatch.com/
[3] https://www.mayoclinic.org/